Report Summary 1. Report Industry Investment Rating No information provided in the content. 2. Core Viewpoints of the Report - The recent volume contraction in the A-share market is a result of technical corrections in over - rising sectors, cautious market sentiment due to Sino - US relations and external uncertainties, and a slowdown in incremental funds. However, it is not a trend reversal. Policy and fundamental factors are expected to boost market confidence, and trading volume may gradually recover [7][8][10]. - It is recommended to continue focusing on two main investment lines: the non - ferrous metals sector and leading stocks in science and technology growth sectors such as semiconductors and artificial intelligence [10]. 3. Summary by Relevant Catalogs Market Review - **Market Performance**: Most major A - share indices rose last week, with the Shanghai 50 having the largest increase (weekly return of - 0.24%). Among major industries, the financial and energy indices performed relatively well (weekly returns of 1.91% and 1.63% respectively), while the information technology and telecommunications service indices performed poorly (weekly returns of - 6.70% and - 4.79% respectively). Among the 30 Shenwan primary industries, 4 industries rose, with banks, coal, and food and beverage having larger increases of 4.89%, 4.17%, and 0.86% respectively; electronics, media, and automobiles had larger declines of 7.14%, 6.27%, and 5.99% respectively [11][16][18]. - **Trading Heat**: The average daily trading volume of the Wind All - A Index last week was 2192.852 billion yuan (previous value: 2602.982 billion yuan), at a relatively high historical level (93.40% of the three - year historical quantile) [21]. - **Valuation Tracking**: As of October 17, 2025, the valuation (PE_TTM) of the Wind All - A Index was 21.96, a decrease of - 0.51 from the previous week, at the 89.20% quantile of the past 5 - year history. Among the 30 Shenwan primary industries, 4 industries saw valuation (PE_TTM) recoveries [26]. Market Observation - **Analysis of Volume Contraction Adjustment**: Last week, the trading volume of major A - share indices declined comprehensively, especially in small - cap and ChiNext and STAR Market sectors. The decline in trading volume was mainly due to technical corrections in over - rising sectors, cautious market sentiment caused by Sino - US relations and external uncertainties, and a slowdown in incremental funds, including cautious northbound funds, cooling margin trading, and increased shareholder reduction pressure [7]. - **Positive Factors**: The upcoming Fourth Plenary Session of the 20th Central Committee may bring continuous policy support in areas such as artificial intelligence and advanced manufacturing. As the third - quarter earnings reports are intensively disclosed, corporate profit situations are becoming clearer, with 82.54% of the 126 companies that have released earnings forecasts reporting positive news. These factors may attract off - market funds to re - enter the market and increase trading volume [8]. - **Investment Recommendations**: Despite the volume contraction adjustment last week, it is not a trend reversal. It is recommended to focus on the non - ferrous metals sector and leading stocks in science and technology growth sectors such as semiconductors and artificial intelligence [10]. Economic Calendar - **Domestic Economic Data**: Key domestic economic data to be released this week include China's unemployment rate, year - on - year growth rate of total retail sales of consumer goods, year - on - year growth rate of quarterly GDP, 1 - year loan prime rate (LPR), and cumulative year - on - year growth rate of urban fixed - asset investment [28]. - **Domestic Important Events**: The National Bureau of Statistics of China will hold a press conference on the economic operation situation [28]. - **Overseas Economic Data**: Overseas economic data to be released include the year - on - year growth rate of US industrial output, unadjusted year - on - year CPI in the US, and Markit composite PMI [28]. - **Overseas Important Events**: Michael Barr, the Vice Chairman of the Federal Reserve for Financial Supervision, will give a speech [28].

Investment Rating - The report maintains a "Buy" rating for key companies in the pharmaceutical and biotechnology sector, including WuXi AppTec, WuXi Biologics, and Changchun High-tech [5][28]. Core Insights - The report expresses a strong outlook on the innovation theme and emphasizes the importance of capturing Q3 performance. The pharmaceutical sector has shown a decline, with the Shanghai Composite Index down 2.73% and the pharmaceutical sector down 3.65% [12][16]. - The report highlights the active participation of Chinese biopharmaceutical companies in global business development (BD) transactions, which have reached 38% of the global total since 2025. This trend is expected to boost investment sentiment in the sector [12][16]. - The report suggests focusing on companies with improving performance metrics, particularly in the CRO/CDMO and upstream segments, as well as in medical devices and traditional Chinese medicine [12][16]. Summary by Sections Industry Overview - The pharmaceutical industry comprises 515 listed companies with a total market capitalization of approximately 731.59 billion yuan and a circulating market value of about 666.30 billion yuan [2]. Market Dynamics - The pharmaceutical sector has experienced a year-to-date return of 18.85%, outperforming the Shanghai Composite Index by 4.13 percentage points. However, recent weeks have seen a decline in various sub-sectors, with traditional Chinese medicine being the only one to show an increase [16][18]. Valuation Metrics - The current valuation of the pharmaceutical sector is approximately 26.2 times PE based on 2025 earnings forecasts, which is a premium of 17.3% compared to the overall A-share market (excluding financials). The TTM valuation stands at 30.1 times PE, below the historical average of 34.9 times PE [18][20]. Key Company Performance - The report lists several companies with strong performance metrics, including WuXi AppTec, WuXi Biologics, and Changchun High-tech, all rated as "Buy." The average decline for recommended stocks in the month was 10.08%, with a weekly decline of 7.43% [28][29]. Business Development Activity - The report notes that several pharmaceutical companies have engaged in overseas licensing agreements, indicating a growing recognition of Chinese companies' capabilities in the global market [12][16]. Regulatory Updates - Recent regulatory announcements from the National Medical Insurance Administration and the National Medical Products Administration are aimed at improving drug pricing transparency and enhancing the approval process for innovative drugs [12][29]. Price Trends - The report tracks the price movements of various vitamins, noting slight decreases in some and stability in others, which may impact the cost structure for companies in the sector [31][32].

Investment Rating - The report maintains an "Overweight" rating for the real estate industry [1] Core Views - The Ministry of Housing and Urban-Rural Development is promoting new urban renewal initiatives, leading to a significant increase in sales on a month-over-month basis despite a year-over-year decline [6] - The report highlights that while sales remain down year-over-year, the recent policies are expected to stabilize the market and improve the performance of financially sound real estate companies [6] Summary by Sections Weekly Market Review - The Shenwan Real Estate Index fell by 2.35%, while the CSI 300 Index decreased by 2.22%, indicating underperformance of the sector compared to the broader market [3][11] Industry Fundamentals - For the week of October 10-16, 38 tracked cities saw a total of 27,488 new homes sold, a year-over-year decline of 19.1% but a month-over-month increase of 257.2% [4][20] - The total transaction area for new homes was 2.804 million square meters, with a year-over-year decrease of 23.3% and a month-over-month increase of 281.4% [4][20] - In the same week, 16 tracked cities recorded 20,896 second-hand homes sold, down 16% year-over-year but up 459.8% month-over-month [35][38] Land Market Supply and Transactions - Land supply for the week was 1,426.4 million square meters, a year-over-year decrease of 70.1%, with an average price of 1,659 yuan per square meter, down 3.9% year-over-year [5] - Land transactions totaled 1,707 million square meters, with a year-over-year increase of 19.4% and a transaction value of 25.88 billion yuan, down 36.3% year-over-year [5] Financing Analysis - Real estate companies issued a total of 5.49 billion yuan in credit bonds, reflecting a year-over-year decrease of 35.64% but a month-over-month increase of 1,272.5% [5] Investment Recommendations - The report suggests focusing on financially stable leading real estate companies such as Yuexiu Property, China Merchants Shekou, Poly Developments, and others, which are expected to effectively navigate market fluctuations [6] - Property management companies are also anticipated to benefit from performance and valuation recovery as market demand rebounds [6]

Investment Rating - The investment rating for the company is "Buy" (maintained) [3][6] Core Views - The company has shown strong revenue growth, with a 17.6% year-on-year increase in the first three quarters of 2025, achieving revenue of 33.3 billion yuan [5][6] - The gross profit margin for Q3 2025 was 37.9%, slightly down from the previous year, but overall profitability remains stable [6] - The company is expanding its production capacity significantly, with investments totaling 90 billion yuan to increase automotive glass production capacity by 46.6 million square meters, which is 32.5% of its 2023 production scale [6] Summary by Sections Financial Performance - For Q3 2025, the company reported revenue of 11.86 billion yuan, a year-on-year increase of 18.9%, and a net profit of 2.26 billion yuan, up 14.1% year-on-year [5][6] - The company forecasts net profits of 9.93 billion yuan, 11.47 billion yuan, and 13.37 billion yuan for 2025, 2026, and 2027 respectively, with growth rates of 32%, 16%, and 17% [6][7] Product and Market Strategy - The company is focusing on high-value-added products, with a 4.9 percentage point increase in the proportion of such products in the first three quarters of 2025, leading to a 6.9% increase in average selling price (ASP) [6] - The company is also enhancing its market share globally, supported by new production capacity in the U.S. and a strong product upgrade strategy [6] Valuation Metrics - The company is expected to have a P/E ratio of 17X, 14X, and 12X for 2025, 2026, and 2027 respectively, indicating a strong valuation outlook [6][7] - The projected return on equity (ROE) is expected to be 22%, 21%, and 19% for the next three years, reflecting solid profitability [6][7]

执业证书编号：S0740523020004 Email：hejy02@zts.com.cn 汽车零部件 执业证书编号：S0740522120003 Email：liuxc03@zts.com.cn 分析师：毛䶮玄 执业证书编号：S0740523020003 Email：maoyx@zts.com.cn 基本状况 | 总股本(百万股) | 434.31 | | --- | --- | | 流通股本(百万股) | 283.30 | | 市价(元) | 30.90 | | 市值(百万元) | 13,420.32 | | 流通市值(百万元) | 8,753.88 | 请务必阅读正文之后的重要声明部分 1、《业绩强劲延续，强客户结构典型 代表》2025-08-27 2、《Q2 超预期，强客户结构典型代 表》2025-07-20 3、《Q1 增长维持强劲，强客户结构 典型代表》2025-04-29 Q3 超预期，强客户结构典型代表 ——博俊科技 2025 三季报预告点评 博俊科技（300926.SZ） 证券研究报告/公司点评报告 2025 年 10 月 19 日 | 评级： | 买入（维持） | 公司盈利预测及估值 | ...

Group 1 - The TACO trading model reflects a dual strategy in US trade negotiations, characterized by public threats and private institutional measures, which have shown limited effectiveness in negotiations with China [3][9][10] - The recent tariff risks have had a muted impact on the market compared to previous instances, indicating that the capital market has adapted to the TACO trading dynamics [11][14] - The resilience of the market is attributed to macroeconomic signals from US officials and strategic partnerships in the tech sector, which have helped stabilize investor sentiment [13][14] Group 2 - The ongoing trade tensions highlight key points of contention, including China's concerns over fentanyl tariffs and the expansion of the entity list, while the US focuses on China's rare earth export controls and agricultural trade [16][17] - Upcoming events, such as the APEC summit and potential tariff escalations, are critical for market sentiment and investment strategies [18] - The long-term impacts of tariffs on the US and Chinese economies remain uncertain, with a focus on the potential for multiple negotiation pathways rather than a singular resolution [18] Group 3 - The domestic bond market is indirectly influenced by TACO trading, with the current US Treasury yields remaining stable within a wide range since September [19][27] - Recent market behavior shows a divergence in bond performance, with a shift in buying power from funds to brokerages, indicating a change in market dynamics [23][24] - The bond market's future is shaped by internal factors, including asset reallocation and the evolving narrative between traditional and new economy sectors [31]

Investment Rating - The report maintains an "Overweight" rating for the coal industry [2][5]. Core Views - The coal price is expected to maintain a strong upward trend due to multiple factors, including supply constraints and increased demand driven by cold winter expectations and export pressures [7][8]. - The report highlights the potential for investment opportunities in the coal sector, particularly in companies with high elasticity in their stock prices [8]. Summary by Sections 1. Industry Overview - The coal industry comprises 37 listed companies with a total market capitalization of 1,954.93 billion yuan and a circulating market value of 1,915.57 billion yuan [2]. 2. Coal Price Trends - The price of thermal coal at the port increased by 43 yuan/ton week-on-week, reaching 753 yuan/ton as of October 17, 2025, marking a 6.06% increase from the previous week [8]. - The average daily production of thermal coal from 462 sample mines was 5.52 million tons, a slight decrease of 0.13% week-on-week and a 3.93% decrease year-on-year [8]. 3. Supply and Demand Dynamics - Supply constraints are expected to persist due to increased safety inspections and anticipated rainfall in major production areas, which may limit coal production and transportation [7][8]. - Demand is bolstered by expectations of a cold winter, leading to early stockpiling by power plants, and ongoing high demand from the steel industry [8]. 4. Key Companies and Recommendations - Recommended high-elasticity stocks include Yanzhou Coal Mining, Shanxi Coal International, and Jinneng Holding, among others, which are expected to benefit from the favorable market conditions [8]. - The report emphasizes the importance of monitoring companies' dividend policies and growth prospects, with several companies expected to maintain or increase their dividend payouts [13]. 5. Market Performance - The coal sector has seen significant price fluctuations, with the report indicating that the coal price is likely to remain resilient despite seasonal trends [8]. - The report notes that the coal sector's performance is expected to improve as supply-demand dynamics become more favorable [8].

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative performance increase of over 15% against the benchmark index within the next 6 to 12 months [7] Core Views - The company has demonstrated strong revenue growth, with a projected increase in operating income from 6,012 million yuan in 2023 to 28,700 million yuan by 2027, reflecting a compound annual growth rate (CAGR) of approximately 39% [3][6] - The net profit attributable to the parent company is expected to rise from 1,263 million yuan in 2023 to 6,359 million yuan in 2027, with a consistent growth rate of around 40% [3][6] - The company is positioned in a high-demand sector, with significant orders reflected in a contract liability of 28 billion yuan as of the end of Q3 2025, indicating robust market demand [5] Summary by Sections Financial Performance - For the first three quarters of 2025, the company achieved revenue of 9,490 million yuan, a year-on-year increase of 54.65%, and a net profit of 1,961 million yuan, up 28.56% [4] - In Q3 2025 alone, revenue reached 4,026 million yuan, marking a 69.60% increase year-on-year and a 31.38% increase quarter-on-quarter [4] Growth Projections - Revenue projections for 2024, 2025, 2026, and 2027 are 9,162 million yuan, 13,760 million yuan, 20,600 million yuan, and 28,700 million yuan respectively, with growth rates of 52%, 50%, and 50% for the following years [3][6] - The expected earnings per share (EPS) are projected to grow from 0.54 yuan in 2023 to 2.74 yuan in 2027 [3][6] Market Position and Strategy - The company is actively expanding its market presence and investing in research and development, with R&D expenses increasing by 42.55% year-on-year in the first three quarters of 2025 [5] - The opening of the HSL protocol is expected to enhance collaboration across the industry, improving efficiency and resource utilization, which will further drive innovation and market growth [5]

Investment Rating - The investment rating for the company is "Buy" (maintained) [4] Core Views - The company reported a revenue of 35.81 billion yuan for the first half of 2025, a year-on-year decrease of 5.9%, with a net loss of 9.45 billion yuan [5] - In Q2, the company achieved a revenue growth of 7.1%, marking a positive turnaround from the previous quarter's decline [6] - The company is accelerating its transition to a subscription model, with subscription-related contract liabilities increasing by 23.6% year-on-year [6] - The AI strategy is being rapidly implemented, with the company integrating various AI models into its product offerings [6] - The company is expanding its global presence, with overseas business revenue growing by 24.9% and new contracts increasing by 42.5% [6] - Adjusted revenue forecasts for 2025, 2026, and 2027 are 96.53 billion yuan, 103.46 billion yuan, and 112.14 billion yuan, respectively, with net profits expected to be -3.10 billion yuan, 1.02 billion yuan, and 4.25 billion yuan [6] Financial Summary - The company's total share capital is 3,417 million shares, with a market price of 15.32 yuan and a market capitalization of 52,348.40 million yuan [1] - The projected operating revenue for 2023A is 9,796 million yuan, with a forecasted decline to 9,153 million yuan in 2024A, followed by a recovery to 9,653 million yuan in 2025E [4] - The projected net profit for 2025E is -310 million yuan, improving to 102 million yuan in 2026E and 425 million yuan in 2027E [4] - The company's cash flow per share is expected to turn positive in 2025E, reaching 0.02 yuan [4]

Investment Rating - The investment rating for the company is "Buy" (maintained) [4] Core Views - The company is increasing its focus on the medical AI sector, accelerating the deployment of AI products [5] - The company's revenue for the first half of 2025 was 839 million yuan, a year-on-year decline of 31.43%, with a net loss of 118 million yuan [5] - The company has adjusted its revenue and profit forecasts for 2025, expecting revenues of 2.725 billion yuan and net profits of 110 million yuan [5] Financial Summary - Total shares outstanding: 2,214.63 million [2] - Market price: 8.81 yuan [2] - Market capitalization: 19,510.87 million yuan [2] - Revenue projections for 2023A to 2027E show fluctuations, with a peak expected in 2027 at 3.176 billion yuan [4] - Net profit projections indicate recovery, with an expected 336 million yuan by 2027 [4] - The company's high-margin software and service revenue accounted for 84.65% of total revenue, up from 73.68% year-on-year [5] - The company has implemented cost-cutting measures, resulting in a 19.07% decrease in sales, management, and R&D expenses [5] AI Product Development - The company is actively enhancing its AI product development, launching the medical large model WinGPT 3.0 and WINEX Copilot 2.2 [5] - These AI products have been deployed in nearly 150 medical institutions, aiding in various medical scenarios [5] - Collaborations with hospitals have been established to enhance AI product capabilities [5]